Delving into the Latest Updates on Armour Therapeutics, Inc. with Synapse

概览

关联

2

项与 Armour Therapeutics, Inc. 相关的药物

AT-012

靶点

relaxin

作用机制

relaxin拮抗剂

在研机构-

原研机构

Armour Therapeutics, Inc.

在研适应症-

非在研适应症

乳腺癌

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

AT-027

靶点

relaxin

作用机制

relaxin拮抗剂

在研机构-

原研机构

Armour Therapeutics, Inc.

在研适应症-

非在研适应症

卵巢癌

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Armour Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Armour Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

2

项与 Armour Therapeutics, Inc. 相关的文献（医药）

2015-11-15·International Journal of Cancer1区 · 医学

Targeting the relaxin hormonal pathway in prostate cancer

1区 · 医学

Review

作者: Summerlee, Alastair J.S. ; Neschadim, Anton ; Silvertown, Joshua D.

Targeting the androgen signalling pathway has long been the hallmark of anti‐hormonal therapy for prostate cancer. However, development of androgen‐independent prostate cancer is an inevitable outcome to therapies targeting this pathway, in part, owing to the shift from cancer dependence on androgen signalling for growth in favor of augmentation of other cellular pathways that provide proliferation‐, survival‐ and angiogenesis‐promoting signals. This review focuses on the role of the hormone relaxin in the development and progression of prostate cancer, prior to and after the onset of androgen independence, as well as its role in cancers of other reproductive tissues. As the body of literature expands, examining relaxin expression in cancerous tissues and its role in a growing number of in vitro and in vivo cancer models, our understanding of the important involvement of this hormone in cancer biology is becoming clearer. Specifically, the pleiotropic functions of relaxin affecting cell growth, angiogenesis, blood flow, cell migration and extracellular matrix remodeling are examined in the context of cancer progression. The interactions and intercepts of the intracellular signalling pathways of relaxin with the androgen pathway are explored in the context of progression of castration‐resistant and androgen‐independent prostate cancers. We provide an overview of current anti‐hormonal therapeutic treatment options for prostate cancer and delve into therapeutic approaches and development of agents aimed at specifically antagonizing relaxin signalling to curb tumor growth. We also discuss the rationale and challenges utilizing such agents as novel anti‐hormonals in the clinic, and their potential to supplement current therapeutic modalities.

2014-06-01·Endocrine-Related Cancer2区 · 医学

Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts

2区 · 医学

Article

作者: Pritzker, Laura B. ; Silvertown, Joshua ; Pritzker, Kenneth P. H. ; Branch, Donald R. ; Neschadim, Anton ; Summerlee, Alastair J. S. ; Trachtenberg, John

Androgen hormones and the androgen receptor (AR) pathway are the main targets of anti-hormonal therapies for prostate cancer. However, resistance inevitably develops to treatments aimed at the AR pathway resulting in androgen-independent or hormone-refractory prostate cancer (HRPC). Therefore, there is a significant unmet need for new, non-androgen anti-hormonal strategies for the management of prostate cancer. We demonstrate that a relaxin hormone receptor antagonist, AT-001, an analog of human H2 relaxin, represents a first-in-class anti-hormonal candidate treatment designed to significantly curtail the growth of androgen-independent human prostate tumor xenografts. Chemically synthesized AT-001, administered subcutaneously, suppressed PC3 xenograft growth by up to 60%. AT-001 also synergized with docetaxel, standard first-line chemotherapy for HRPC, to suppress tumor growth by more than 98% in PC3 xenografts via a mechanism involving the downregulation of hypoxia-inducible factor 1 alpha and the hypoxia-induced response. Our data support developing AT-001 for clinical use as an anti-relaxin hormonal therapy for advanced prostate cancer.

100 项与 Armour Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Armour Therapeutics, Inc. 相关的转化医学

登录后查看更多信息